A lot has changed in the world of HIV clinical science since last year's IDWeek meeting. In the past year, groundbreaking clinical data have dramatically reshaped the way the medical community thinks about HIV treatment.
Some new revelations have been frustrating setbacks. For example, the relapse of the "Mississippi baby" made it clear that there is still more work to be done to disrupt latent reservoirs of HIV.
Yet other research has led to dramatic changes in treatment guidelines, such as the new World Health Organization (WHO) guidelines that now recommend antiretroviral treatment (ART) for all newly diagnosed patients, regardless of their CD4+ count.
During a keynote symposium at IDWeek 2015 in San Diego, California, Adaora Adimora, M.D., M.P.H., a professor of medicine and epidemiology at the University of North Carolina, offered a comprehensive look back at the last year of clinical science in HIV.